Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS231295 in Advanced Solid Malignant Tumors
NCT07612488Phase 1Not yet recruiting
- Sponsor
- ThalassaX Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS231295 in solid tumor (advanced stage), sponsored by ThalassaX Therapeutics. Primary endpoints: Adverse Events, Dose Limiting Toxicity at 34 days and 9 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CS231295
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07612488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612488.